cation of the mitomycin C to the periphery of the treatment zone, the safety may be enhanced without loss of effi cacy.

subepithelial haze (10 of 14 patients in our series had preexisting haze). Patient symptoms. In our retrospective noncomparative case series, symptoms were not systematically recorded in all patients. We reviewed the charts for the presence of symptoms of ghosting, halo, glare, and night driving disability. Glare and halos were reported in two patients before retreatment, resolving in one patient and persisting in another patient. Five patients had documentation of the absence of these symptoms before retreatment, and nine patients had similar documentation after retreatment. Laser used for retreatment. We believe that our technique could be performed using most lasers currently available in the United States. The retreatments in our study were performed before 1998. The VISX 20/20 laser, VISX Excimer Laser (VISX, Santa Clara, CA) was used in 2 patients and the Summit ExciMed, Summit ExciMed Laser (Summit Technology Waltham, MA) in 12 patients. Spherical equivalent range before retreatment. The mean spherical equivalent before retreatment was 2.3 diopters (D) the standard deviation was 1.2 D, and the range was 0.75 to 3.63 D. Epithelial wound healing. We did not perform the primary surgery on several of the patients included in this study. Although we agree with Dr. Huang that the two patients in whom epithelial wound healing after the primary procedure exceeded 30 days may have had an underlying pathologic condition, we noted that epithelial closure in both patients was complete by the fourth day after the retreatment. We hope that this information will be useful. We believe that our reported technique of transepithelial PTK–PRK guided by epithelial fl uorescence, without modulating agents, and followed by 3–15 pulses of PTK (sought to confi rm the absence of residual epithelium in the treatment area) is useful in improving uncorrected visual acuity and in reducing decentrations and central islands. In patients with subepithelial scarring, we currently add a fi nal step of mitomycin-C annular treatment. 2,3 This approach is a modifi